Managing the risk of lithium-induced nephropathy in the long-term treatment of patients with recurrent affective disorders

BMC Medicine

Michael Bauer¹  Emanuel Severus¹ 

[1] Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstr. 74, D-01307 Dresden, Germany

关键词: shared decision making.;    chronic kidney disease;    affective disorders;    lithium;   

Others  :  857196
DOI  :  10.1186/1741-7015-11-34

 received in 2013-01-22, accepted in 2013-02-11,  发布年份 2013

【 摘 要 】

Lithium has been the most effective psychopharmacological drug in the long-term treatment of patients with recurrent unipolar and bipolar affective illness. As a result of its widespread and longtime use in patients with recurrent affective disorders, psychiatrists have become increasingly aware of the whole spectrum of lithium's potential side effects. One of the side effects associated with its chronic use is lithium-induced nephropathy. In a recent cross-sectional study published in BMC Medicine, Alberto Bocchetta et al. add further information to this topic, demonstrating that duration of lithium treatment is associated with impaired glomerular function in patients with recurrent or chronic affective disorders. The present paper will discuss the implications of this and other related recent research on our management of patients with recurrent affective disorders. In this context the importance of shared decision making and close monitoring of kidney function is highlighted, including the regular assessment of the glomerular filtration rate, to provide best possible care to our patients maintained on lithium treatment.

See related research article here http://www.biomedcentral.com/1741-7015/11/33 webcite

【 授权许可】

   
2013 Severus and Bauer; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Pfennig A, Bschor T, Baghai T, Braunig P, Brieger P, Falkai P, Geissler D, Gielen R, Giesler H, Gruber O, Kopp I, Meyer TD, Mohrmann KH, Muche-Borowski C, Padberg F, Scherk H, Strech D, Bauer M: [S3 guidelines on diagnostics and therapy of bipolar disorders: development process and essential recommendations]. Nervenarzt 2012, 83:568-586. Article in German
• [2]Grunfeld JP, Rossier BC: Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009, 5:270-276.
• [3]Bocchetta A, Ardau R, Carta P, Ligas F, Sardu C, Pani A, Del Zompo M: Duration of lithium treatment is a risk factor for reduced glomerular function: a cross-sectional study. BMC Med 2013, 11:33. BioMed Central Full Text
• [4]Bassilios N, Martel P, Godard V, Froissart M, Grunfeld JP, Stengel B: Monitoring of glomerular filtration rate in lithium-treated outpatients--an ambulatory laboratory database surveillance. Nephrol Dial Transplant 2008, 23:562-565.
• [5]Tredget J, Kirov A, Kirov G: Effects of chronic lithium treatment on renal function. J Affect Disord 2010, 126:436-440.
• [6]McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR: Lithium toxicity profile: a systematic review and meta-analysis. Lancet 2012, 379:721-728.
• [7]Levey AS, de Jong PE, Coresh J, El NM, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011, 80:17-28.
• [8]Muller-Oerlinghausen B, Bauer M, Grof P: Commentary on a recent review of lithium toxicity: what are its implications for clinical practice? BMC Med 2012, 10:132. BioMed Central Full Text
• [9]Jefferson JW: A clinician's guide to monitoring kidney function in lithium-treated patients. J Clin Psychiatry 2010, 71:1153-1157.
• [10]Morriss R, Benjamin B: Lithium and eGFR: a new routinely available tool for the prevention of chronic kidney disease. Br J Psychiatry 2008, 193:93-95.
• [11]eGFR Calculator [http://www.renal.org/egfrcalc/] webcite
• [12]Presne C, Fakhouri F, Noel LH, Stengel B, Even C, Kreis H, Mignon F, Grunfeld JP: Lithium-induced nephropathy: Rate of progression and prognostic factors. Kidney Int 2003, 64:585-592.